基于社区的多基因药基因组测试是可行的,并降低了医疗保健总成本
Nihal El Rouby1,2, Josiah D Allen1, Tyler Koep3
1St Elizabeth Healthcare, Edgewood, Kentucky, USA.
Clinical and translational science
|November 27, 2025
概括
在医疗保险患者的多基因药基因组 (mgPGx) 测试显示了成本节约. 这种药物基因组测试确定了可操作的结果,表明改善医疗保健经济学的潜力.
科学领域:
- 药物基因组学 药物基因组学
- 卫生经济学 卫生经济学
- 临床药房 临床药房
背景情况:
- 已知药基因组 (PGx) 测试,特别是多基因组 (mgPGx),可以提高临床结果.
- 关于mgPGx测试对经济的影响的现实数据有限.
- 了解mgPGx的经济价值对于广泛的临床采用至关重要.
研究的目的:
- 评估社区卫生系统中医疗保险患者mgPGx测试的实用性和经济价值.
- 评估PGx药物的患病率,涉及PGx药物的多药店,以及可操作的PGx结果.
- 为了比较mgPGx测试的患者和匹配的对照组之间的护理总成本 (TCOC).
主要方法:
- 在社区卫生系统中,一组1042名医疗保险优势患者接受了mgPGx测试.
- 一个分层算法识别了服用至少一种PGx引导药物的患者.
- 倾向性得分匹配被用来比较TCOC超过12个月的548名测试患者和对照组.
主要成果:
- 44%的患者服用了三种或更多的PGx导向药物.
- 其中超过三分之一的患者 (35.5%) 至少有两个可操作的PGx结果.
- 观察到每名会员每年净成本节省1827美元的趋势,包括医疗和药房节省.
结论:
- 涉及PGx药物的多药在这个患者群体中很常见.
- mgPGx测试显示了大幅节省成本的趋势.
- 需要对更大的样本进行进一步的研究,以证实这些经济发现并评估长期影响.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
657
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
657
01:11Genome-wide Association Studies-GWAS
15.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.2K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
03:00Next-generation Sequencing
97.6K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
97.6K
01:29Issues And Trends In Healthcare Delivery System
6.1K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.1K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141